BioPharma Resources

Investigational drug · Phase 3

Elritercept

Also called: TAK-226, KER-050

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelodysplastic Syndromes, Myelofibrosis, Anemia.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

6

Any phase or sponsor naming "Elritercept"

First trial start

2020

Aug 19, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Elritercept", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Myelodysplastic Syndromes
  • Myelofibrosis
  • Anemia
  • Cytopenia
  • Myelodysplastic Syndrome

Approved drugs for the same conditions: Myelodysplastic syndromes · Myelofibrosis · Anemia · Hematology and blood cancers · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Elritercept" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Myelodysplastic Syndromes

  • AND017Phase 36 trials

    Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia

  • BL-M11D1Phase 32 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes

  • RoxadustatFG-4592, ASP1517Phase 32 trials

    Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes

  • ASTX030cedazuridine + azacitidinePhase 31 trial

    Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm

  • RimiducidAP1903Phase 23 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • bexmarilimabFP-1305Phase 22 trials

    Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

  • DISC-0974Phase 22 trials

    Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia

  • OfirnoflastHT-6184Phase 22 trials

    Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.